ImmunityBio (IBRX) Income towards Parent Company (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Income towards Parent Company data on file, last reported at -$632.8 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 388.01% year-over-year to -$632.8 million in Q1 2026; TTM through Mar 2026 was -$854.6 million, a 108.86% decrease from a year earlier, with the FY2025 full-year figure at -$351.5 million, up 15.03% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$632.8 million, down from -$62.0 million in the prior quarter.
• Over the last five years, Income towards Parent Company for IBRX reached as high as -$59.2 million in Q4 2024 and fell as low as -$632.8 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Across the five-year window, Income towards Parent Company jumped 74.65% in 2024 and sank 388.01% in 2026, its largest moves.
• Year by year, Income towards Parent Company stood at -$108.3 million in 2022, then tumbled by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then slipped by 4.7% to -$62.0 million in 2025, then slumped by 921.32% to -$632.8 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$632.8 million in Q1 2026, -$62.0 million in Q4 2025, and -$67.3 million in Q3 2025.